Are Women Who Work in Bars, Guesthouses and Similar Facilities a Suitable Study Population for Vaginal Microbicide Trials in Africa? Authors: Andrew Vallely, Ian R. Hambleton, Stella Kasindi, Louise Knight, Suzanna C. Francis, Tobias Chirwa, Dean Everett, Charles Shagi, Claire Cook, Celia Barberousse, Deborah Watson-Jones, John Changalucha, David Ross, Richard J. Hayes Published: 2010, PLOS ONE DOI: 10.1371/journal.pone.0010661 ABSTRACT A feasibility study was conducted to investigate whether an occupational at-risk cohort of women in Mwanza, Tanzania are a suitable study population for future phase III vaginal microbicide trials. 1573 women aged 16–54 y working in traditional and modern bars, restaurants, hotels, guesthouses or as local food-handlers were enrolled at community-based reproductive health clinics, provided specimens for HIV/STI and pregnancy testing, and asked to attend three-monthly clinical follow-up visits for 12-months. HIV positive and negative women were eligible to enter the feasibility study and to receive free reproductive health services at any time. HIV prevalence at baseline was 26.5% (417/1573). HIV incidence among 1156 sero-negative women attending at baseline was 2.9/100PYs. Among 1020 HIV sero-negative, non-pregnant women, HIV incidence was 2.0/100PYs, HSV-2 incidence 12.7/100PYs and pregnancy rate 17.8/100PYs. Retention at three-months was 76.3% (778/1020). Among 771 HIV sero-negative, non-pregnant women attending at three-months, subsequent follow-up at 6, 9 and 12-months was 83.7%, 79.6%, and 72.1% respectively. Older women, those who had not moved home or changed their place of work in the last year, and women working in traditional bars or as local food handlers had the highest re-attendance. Women working in food outlets and recreational facilities in Tanzania and other parts of Africa may be a suitable study population for microbicide and other HIV prevention trials. Effective locally-appropriate strategies to address high pregnancy rates and early losses to follow-up are essential to minimise risk to clinical trials in these settings. INTRODUCTION In many developed and developing countries, HIV prevention trials are usually undertaken among vulnerable, disadvantaged communities at high-risk of HIV and STIs, where HIV incidence rates make randomised controlled clinical trials feasible [1] , [2] but where poverty and social exclusion mean ethical considerations are paramount [3] , [4] . Such populations may include female sex workers, injecting drug users, men who have sex with men, prison inmates and the homeless [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] . There are considerable ethical and logistical challenges to consider when planning HIV prevention trials in such populations, for example, the need to develop effective locally-appropriate informed consent procedures [4] , [15] , [16] , [17] , [18] , [19] , of ensuring that trial participation does not exacerbate stigma, vulnerability or social harm [20] , [21] , [22] ; and to ensure that appropriate locally-agreed standards of clinical care are made available to trial participants, particularly those who seroconvert during the trial or who are HIV positive at screening [23] , [24] , [25] . Recruiting and retaining participants from high-risk cohorts is often problematic. In many settings it is difficult to access and meaningfully engage with vulnerable groups in the community [11] , [12] . Providing accurate information about trial objectives and procedures; dispelling fears around disclosure and confidentiality; and reducing distrust and suspicion between potential participants and external researchers may therefore be difficult, and may hinder trial enrolment. High mobility is common in many vulnerable groups, which makes tracing those who default from follow-up difficult, necessitating the use of community fieldworkers or peer educators [26] . Volunteers from vulnerable groups may be reluctant to attend established health services due to travel and opportunity costs and the way in which they are treated by health centre staff so that it is often necessary to establish community-based study clinics, which may need to operate at unusual hours or at weekends in order to encourage potential participants to attend [4] , [12] , [26] . In addition to these considerations, researchers planning vaginal microbicide trials also need to take into account pregnancy rates and the prevalence and nature of intravaginal hygiene practices in any proposed study population. The search for female-controlled methods of HIV prevention has led to a concerted international effort to develop vaginal microbicides: topical chemical agents, which when administered vaginally prior to sexual intercourse would prevent HIV and ideally other sexually transmitted infections (STIs) [27] , [28] . Mwanza is one of six centres in Sub-Saharan Africa participating in the Microbicides Development Programme (MDP), an international partnership for the development of vaginal microbicides for HIV prevention, funded by the UK Department for International Development and Medical Research Council (MRC) [29] . In preparation for the MDP301 randomised placebo-controlled efficacy and safety trial of the candidate vaginal microbicide PRO2000/5 Gel (Indevus Pharmaceuticals, USA), we carried out a feasibility study in an occupational cohort of women at high-risk of HIV/STIs in ten administrative wards in Mwanza City, northern Tanzania between July 2002 and December 2004. Women working in food and recreational facilities, including modern bars, traditional bars ( vilabu or pombe shops), restaurants, hotels, guesthouses, groceries and as informal food vendors ( mamalishe ), were eligible to participate. In Tanzania, high rates of HIV and STIs have been reported among women working in such facilities in areas situated along major transit routes [30] , [31] , [32] , [33] and in commercial centres adjacent to newly-established goldmines [34] , [35] . Some women in this occupational group are reported to periodically supplement their income through transactional sex [35] , [36] and, although not necessarily perceived as commercial sex workers within the wider community, are nonetheless at increased risk of STIs and HIV infection [31] , [33] , [34] . The objectives of the feasibility study were to: test the feasibility of recruiting and retaining sufficient numbers of women for a subsequent microbicides trial; assess baseline HIV and STI prevalence, HIV incidence and pregnancy rates; investigate methods for improving the reliability and validity of reported sexual behaviour data including condom use and intravaginal practices; and investigate the acceptability of vaginal microbicide gels among women and their sexual partners. The baseline socio-demographic and behavioural characteristics of 1573 participants enrolled in the feasibility study and the factors associated with loss to follow-up at three-months have previously been described [37] . In this paper, we present data on cohort retention, factors associated with loss to follow-up, and HIV, STI and pregnancy incidence over 12 months of follow-up among initially HIV sero-negative, non-pregnant women who would be eligible for future phase III HIV prevention trials. We use the findings to examine whether this is a suitable study population in which to conduct such clinical trials in Africa. METHODS The design of the study, study population and laboratory methods have been described previously [37] . Briefly, following participatory community mobilisation and mapping activities, weekly community-based reproductive health clinics were established in selected guesthouses in ten administrative wards in Mwanza City, northern Tanzania by October 2002. In order to avoid exacerbating stigma, social exclusion or harm as a result of study participation and to investigate the feasibility of recruiting women for a variety of future HIV-related clinical research activities both HIV positive and negative women were eligible to participate in the Mwanza feasibility study. The study design did not therefore include a preliminary screening assessment (e.g. to confirm negative HIV and pregnancy status) and participants were directly enrolled at their first clinic visit. STUDY PROCEDURES AND INVESTIGATIONS Free reproductive health services, including syndromic management of STIs, family planning, health education, and voluntary HIV counselling and testing (VCT) were provided. Participants were asked to attend a study clinic every three months, when a study nurse collected demographic and sexual behaviour information using a pre-tested questionnaire in Swahili. A gynaecological examination was offered at entry and six monthly clinical follow-up visits when vaginal swabs for bacterial vaginosis and Trichomonas vaginalis , cervical swabs for Neisseria gonorrhoeae and Chlamydia trachomatis , urine for pregnancy testing and venous blood for HIV, syphilis and Herpes simplex type-2 (HSV-2) serology were also collected. Women with symptoms and clinical signs of STIs were managed according to Tanzanian national syndromic management guidelines [38] . Women were encouraged to use the free drop-in reproductive health service at any time between booked appointments. ETHICS Ethical clearance was obtained from the National Medical Research Coordinating Committee in Tanzania and the Ethics Committee of the London School of Hygiene and Tropical Medicine, UK. Written informed consent (signature or witnessed thumbprint) was obtained from all participants prior to enrolment. STATISTICAL METHODS Data were double-entered and verified. We calculated attendance rates at three-monthly visits for three distinct groups: the complete cohort of HIV positive and negative women attending a baseline clinic visit (N = 1573); all HIV-negative, non-pregnant women from this complete baseline cohort (N = 1020); and all HIV-negative, non-pregnant women who attended a first follow-up visit at three-months (N = 771) ( Figure 1 ). The sub-cohorts of 1020 and 771 subjects represent women who would be considered broadly eligible for entry into a phase III vaginal microbicide trial such as MDP301. Due to the lack of a screening visit in the Mwanza feasibility study design we considered that retention rates among the sub-cohort of 771 ‘eligible’ women who re-attended for the first follow-up visit were more likely to be predictive of future retention in a phase III clinical trial in this setting than in the larger sub-cohort of 1020 women or the complete cohort of 1573 subjects. We present selected characteristics of ‘eligible’ women, stratified by the type of facility in which they are employed ( mamalishe or pombe shop, guesthouse or hotel, restaurant or bar or grocery). We calculated the baseline prevalence and incidence of pregnancy and serological markers including HIV; and the prevalence of STIs and aspects of sexual behaviour at each follow-up visit. We tested for trends in prevalence over time by fitting a longitudinal logistic regression model for each STI and sexual behaviour outcome, which allowed for correlations induced by repeat visits of each participant. We included time in each model by including visit attendance (baseline then three-monthly follow-up over 12-months), and assessed its effect using a likelihood ratio test. To examine factors contributing to cohort re-attendance, we created a new variable for the number of follow-up visits attended after the three-month clinic visit (‘attendance’). Each participant could therefore miss one, two, or three subsequent visits. We treated this outcome variable as ordinal and used ordinal logistic regression to examine factors associated with re-attendance, so that an odds ratio >1.0 was associated with a better attendance profile. Models were adjusted for age, clinic site, facility type, and other variables that were statistically significant (P<0.05). For this regression analysis we constructed two composite variables with three levels (low, moderate and high): ‘travel’ based on time away from home, and ‘permanence’ based on moving home or job in the previous year. We used Stata for all analyses (Version 10, StataCorp LP, College Station, Texas, US). RESULTS Participatory community mapping conducted in March 2002 showed that there were around 2494 women working in 953 food and recreational facilities in ten administrative wards in Mwanza City [37] . Of 1573 women attending a first clinic visit, 1020 (64.8%) were HIV sero-negative, had a negative urine pregnancy test and would have been considered broadly eligible for enrolment into a future vaginal microbicide trial ( Table 1 ). Around 24% (242/1020) of women in this sub-population failed to re-attend a second clinic visit at three-months; subsequent retention was also poor in this group. Of the 778 women who re-attended at three-months, 771 would have been considered eligible for enrolment into a future microbicide trial based on the above criteria. Re-attendance in this sub-population at subsequent three-monthly clinical follow-up visits was 83.7%, 79.6% and 72.1%. 1 At baseline, there were 1573 attendees. Of these 1156 (73.5%) were HIV negative, 1409 (89.6%) were not pregnant, and 1020 (64.8%) were both HIV negative and not-pregnant and therefore met broad eligibility criteria for enrolment into a future microbicide trial. 2 At the 3-month clinic visit, 778/1020 (76.3%) women originally considered eligible for enrolment re-attended; 7/778 women sero-converted between baseline and 3 mo. visits leaving a total of 771 ‘eligible’ women at 3-months. 3 Attendance  =  % of all possible follow-up visits that were actually attended. The socio-demographic characteristics of the 1020 eligible women attending at baseline and the 771 eligible women attending at three-months were broadly similar in terms of facility type, level of education, literacy and ethnicity ( Table 2 ) and reflected the distribution observed in the full feasibility study cohort of 1573 women [37] . Comparing the 242 women who did not attend at three-months with the 778 women who did, women who did not re-attend tended to be younger (difference in mean age 4.9 y; p<0.001); were less likely to be married (p<0.001); had travelled more frequently in the three-months before recruitment (difference in travel scores p = 0.01); and were more mobile in terms of recent changes in accommodation and place of work (difference in permanence scores p<0.001). 1 One participant with no recorded age; 2 Travel in the three months preceding baseline clinic visit was categorised as: Low (zero nights away from home), Moderate (≥1 night but less than one continuous week away from home) and High (≥1 continuous week away from home on one or more occasions); 3 Permanence of home and workplace location was categorised as: High (lived in the same house and worked at the same facility during the past year); Moderate (lived or worked at the same location for <1 year and moved house no more than once in the previous year); Low (lived or worked at the same location for <1 year and moved house twice or more in the previous year). TABLE: Re-attendance among women eligible to enrol in a future microbicide trial. Attendance Visit Full cohort Eligible and attending at baseline 1 Eligible and attending at 3 mo. 2 Baseline 1573 1020 3 month 1165 (74.1%) 778 (76.3%) 771 6 month 1079 (68.6%) 726 (71.2%) 645 (83.7%) 9 month 1006 (64.0%) 680 (66.7%) 614 (79.6%) 12 month 905 (57.5%) 607 (59.5%) 556 (72.1%) Overall attendance rate at 12-months (95% CI) 3 66.0% (64.9–67.2) 68.4% (67.0–69.8) 78.5% (76.7–80.1) TABLE: Selected socio-demographic characteristics of eligible sub-cohorts at baseline (n = 1020) and 3 mo. visit (n = 771). Baseline (n  = 1020) 3-months (n = 771) Mamalishe/Pombe (n = 654; 64.1%) Guesthouse/Hotel (n = 164; 16.1%) Restaurant/Bar/Grocery (n = 202; 19.8%) All (N = 1020) Mamalishe/Pombe (n = 517; 67.1%) Guesthouse/Hotel (n = 115; 14.9%) Restaurant/Bar/Grocery (n = 139; 18.0%) All (N = 771) Age (mean, SD) 30.8 (8.7) 27.1 (6.5) 27.1 (7.0) 29.5 (8.2) 31.9 (8.7) 28.2 (6.8) 28.0 (7.0) 30.6 (8.4) Age (years) 1 <20 49 (7.5%) 16 (9.8%) 20 (9.9%) 85 (8.3%) 25 (4.8%) 6 (5.2%) 10 (7.2%) 41 (5.3%) 20–24 124 (19.0%) 50 (30.5%) 71 (35.2%) 245 (24.0%) 89 (17.3%) 34 (29.6%) 41 (29.5%) 164 (21.3%) 25–34 274 (42.0%) 76 (46.3%) 86 (42.6%) 436 (42.8%) 213 (41.3%) 54 (47.0%) 69 (49.6%) 336 (43.6%) 35+ 206 (31.6%) 22 (13.4%) 25 (12.4%) 253 (24.8%) 189 (36.6%) 21 (18.3%) 19 (13.7%) 229 (29.7%) Education Primary incomplete 184 (28.1%) 22 (13.4%) 37 (18.3%) 243 (23.8%) 144 (27.9%) 16 (13.9%) 25 (18.0%) 185 (24.0%) Primary complete 422 (64.5%) 94 (57.3%) 142 (70.3%) 658 (64.5%) 336 (65.0%) 63 (54.8%) 94 (67.6%) 493 (63.9%) Secondary 30 (4.6%) 43 (26.2%) 19 (9.4%) 92 (9.0%) 21 (4.1%) 33 (28.7%) 16 (11.5%) 70 (9.1%) Other 18 (2.8%) 5 (3.1%) 4 (2.0%) 27 (2.7%) 16 (3.1%) 3 (2.6%) 4 (2.9%) 23 (3.0%) Marital status Married 342 (52.3%) 23 (14.0%) 38 (18.8%) 403 (39.5%) 282 (54.6%) 16 (13.9%) 26 (18.7%) 324 (42.0%) Separated/divorced/widowed 218 (33.3%) 78 (47.6%) 97 (48.0%) 393 (38.5%) 177 (34.2%) 55 (47.8%) 67 (48.2%) 299 (38.8%) Single 94 (14.4%) 63 (38.4%) 67 (33.2%) 224 (22.0%) 58 (11.2%) 44 (38.3%) 46 (33.1%) 148 (19.2%) Ethnic group Sukuma 231 (35.3%) 63 (38.4%) 63 (31.2%) 357 (35.0%) 185 (35.8%) 41 (35.7%) 43 (30.9%) 269 (34.9%) Other 423 (64.7%) 101 (61.6%) 139 (68.8%) 663 (65.0%) 332 (64.2%) 74 (64.4%) 96 (69.1%) 502 (65.1%) Literacy No 124 (19.0%) 16 (9.8%) 25 (12.4%) 165 (16.2%) 101 (19.5%) 12 (10.4%) 14 (10.1%) 127 (16.5%) Yes 530 (81.0%) 148 (90.2%) 177 (87.6%) 855 (83.8%) 416 (80.5%) 103 (89.6%) 125 (89.9%) 644 (83.5%) Travel 2 Low 488 (74.6%) 88 (53.7%) 114 (57.0%) 690 (67.8%) 383 (74.1%) 68 (59.1%) 76 (55.1%) 527 (68.4%) Moderate 146 (22.3%) 60 (36.6%) 63 (31.5%) 269 (26.4%) 121 (23.4%) 39 (33.9%) 48 (34.8%) 208 (27.0%) High 20 (3.1%) 16 (9.8%) 23 (11.5%) 59 (5.8%) 13 (2.5%) 8 (7.0%) 14 (10.1%) 35 (4.6%) Permanence 3 High 315 (48.2%) 45 (27.6%) 45 (22.3%) 405 (39.8%) 269 (52.1%) 34 (29.8%) 39 (28.1%) 342 (44.5%) Moderate 165 (25.3%) 51 (31.3%) 63 (31.2%) 279 (27.4%) 127 (24.6%) 35 (30.7%) 44 (31.7%) 206 (26.8%) Low 173 (26.5%) 67 (41.1%) 94 (46.5%) 334 (32.8%) 120 (23.3%) 45 (39.5%) 56 (40.3%) 221 (28.7%) PREVALENCE AND INCIDENCE OF PREGNANCY, HIV AND STI Baseline HIV and STI prevalences have been reported elsewhere [37] but in brief, among the 1573 women who attended a first clinic visit, the prevalence of HIV was 26.5%; pregnancy 9.6%; HSV-2 infection 74.1%; active syphilis (TPPA+/RPR+) 10.1%, bacterial vaginosis 50.7%; gonorrhoea 5.3%; chlamydia 5.7% and trichomoniasis 12.3%. HIV prevalence at baseline increased with age, was lower among local food-handlers ( mamalishe ) and women working in traditional bars, married women and those with fewer sexual partners, and was associated with HSV-2 infection and bacterial vaginosis. The incidence of HIV among all women who were sero-negative at baseline (1156/1573) was 2.9 per 100 person-years (PYs) (95%CI:1.9–4.3). HIV incidence among mamalishe /pombe shop workers (2.0/100PYs [95%CI:1.1–3.6]) and guesthouse/hotel workers (3.5/100PYs [95%CI:1.3–9.3]) was lower than among restaurant/bar workers (5.7/100PYs [95%CI:2.9–11.4]). HIV incidence was highest in those aged 25–34years (4.3/100PYs [95%CI:2.6–7.1]) among whom 15 of the 23 (65%) sero-conversions observed in this sub-population occurred (data not shown). In the sub-cohort of 1020 eligible (HIV sero-negative, non-pregnant) women who attended at baseline the incidence of HIV was 2.0/100PYs ( Table 3 ). HIV incidence among mamalishe /pombe shop workers (1.6/100PYs) and guesthouse/hotel workers (1.0/100PYs) was again lower than among restaurant/bar workers (4.1/100PYs). The incidence of pregnancy in this sub-cohort was 17.8/100PYs and HSV-2 incidence 12.7/100PYs. 1. Participants were tested for each incident endpoint at baseline, and at three-monthly intervals during follow-up. Incidence was calculated as the number of new cases divided by the total time in years that participants remained in the study without the incident endpoint of interest. Following standard practice, participants were considered censored at their last recorded study visit. 2. Pregnancy and HIV seropositive status were initial study exclusion criteria. By definition, HIV prevalence was therefore zero among 1020 eligible women at baseline. 3. Incident cases were defined as those who tested positive for both TPPA and RPR for the first time during follow-up and exclude women with active syphilis (TPPA+ and RPR+) at baseline. The prevalence of gonorrhoea, chlamydia and bacterial vaginosis was significantly lower at 6 and 12-months compared to baseline ( Table 4 ). The prevalence of trichomoniasis also fell from 12.3% at baseline to 6.5% at 12-months (p = 0.09). 1. For each variable, we modelled the change in prevalence between visits using a random-effects logistic regression model adjusting for visit as a continuous variable and including a random intercept. This modelling approach adjusted for the expected additional correlation between multiple responses by the same participant. We calculated formal tests of significance using likelihood ratio tests, and the p-values from these tests are presented in the final column of the table. 2. T. vaginalis sample N = 220. Measurements made at recruitment (visit 1) and at 12 months (visit 5). 3. Pregnancy status was an initial study exclusion criterion. Prevalence at Visit 01 was therefore zero among eligible participants. TABLE: Prevalence and incidence of pregnancy, HIV and STIs among eligible women attending at baseline (n = 1020). Baseline (n = 1020) Pregnancy and serological markers Prevalent cases Participants tested Baseline Prevalence New Cases Person years (PYs) incidence rate per 100 PYs (95% CI) 1 Pregnancy 0 1020 - 2 111 623.8 17.8 (14.8–21.4) Serology HIV 0 1020 - 2 14 713.8 2.0 (1.2–3.3) HSV-2 703 1019 69.0% 19 150.2 12.7 (8.1–19.8) TPPA+/RPR+ 3 98 1018 9.6% 14 598.0 2.3 (1.4–4.0) HIV incidence by facility type Mamalishe/pombe 0 654 - 2 8 493.5 1.6 (0.8–3.2) Guesthouse/hotel 0 164 - 2 1 96.1 1.0 (0.1–7.4) Restaurant/bar/grocery 0 202 - 2 5 123.3 4.1 (1.7–9.7) TABLE: Prevalence of STIs, pregnancy, contraception and reported sexual behaviour at baseline and scheduled follow-up visits among 1020 potential trial participants. Baseline (n = 1020) 3 mo. (n = 778) 6 mo. (n = 726) 9 mo. (n = 680) 12 mo. (n = 607) Odds Ratio/P-value 1 Genital swabs  N gonorrhoeae (NG) 5.3% (52/986) - 1.7% (11/631) - 1.7% (7/433) 0.66 (0.54–0.82) p<0.001  C trachomatis (CT) 5.5% (54/986) - 1.3% (8/631) - 3.0% (13/433) 0.75 (0.62–0.90) p = 0.001  T vaginalis 2 12.3% (27/220) - - - 6.5% (7/107) 0.81 (0.62–1.05) p = 0.09 Bacterial vaginosis 48.1% (485/987) - 38.4% (246/641) - - 0.75 (0.66–0.84) p<0.001 Pregnancy 1.09 (0.72–1.64) p = 0.69 Yes - 3 - 10.0% - 9.3% Contraceptive prevalence 1.26 (1.17–1.36) p<0.001 Yes (all methods) 33.9% 34.3% 35.2% 37.5% 43.3% Contraceptive methods Condom 6.3% 7.4% 8.4% 5.9% 9.3% 1.19 (1.05–1.35) p = 0.005 Pill/injection/IUCD 23.4% 20.4% 19.4% 21.9% 24.0% 1.10 (0.99–1.22) p = 0.08 Traditional/safe period/other 4.2% 6.6% 7.4% 9.7% 10.0% 1.44 (1.26–1.64) p<0.001 Planning pregnancy in next three months 0.62 (0.51–0.75) p<0.001 Yes 21.0% 14.0% 11.6% 7.4% 7.0% Partners in past three months 1.72 (1.54–1.92) p<0.001 Two or more 19.6% 8.9% 7.5% 6.1% 5.8% Condom use with regular partner 1.06 (0.95–1.17) p = 0.32 Always 10.2% 12.8% 12.3% 12.1% 10.7% Condom use with other partners 1.57 (1.28–1.93) p<0.001 Always 34.3% 50.0% 62.7% 62.8% 57.4% Cleaned inside vagina in past three months 1.25 (1.16–1.34) p<0.001 Yes 73.7% 85.2% 88.1% 85.6% 83.6% Chance of catching HIV 0.86 (0.79–0.94) p = 0.001 Likely 89.5% 87.9% 84.6% 87.7% 83.7% SEXUAL BEHAVIOUR, CONDOM USE AND CONTRACEPTION The proportion of women reporting two or more sexual partners at each clinical follow-up visit was significantly less than at baseline (p<0.001), whilst consistent condom use with non-regular partners was significantly higher at each time point (p<0.001; Table 4 ). There were no significant changes observed in reported condom use with regular partner. The prevalence of reported vaginal cleansing was significantly higher during follow-up than at baseline (p<0.001). A significant reduction was seen in the proportion of women who perceived themselves to be at high risk of HIV acquisition (p = 0.001). Among the 1573 women attending a first clinic visit, anal sex in the previous three-months was reported by ≤1% at baseline, 6 and 12-months (data not shown). Reported intent to become pregnant was significantly lower at each follow-up visit than at baseline (p<0.001) with a significant increase also observed in contraceptive prevalence (all methods combined) (p<0.001). However, there was no significant change in the proportion of women using highly effective contraceptive methods (pills/injection/IUCD) (p = 0.08) and the proportion of women with positive urine pregnancy tests at baseline, 6 and 12-months were similar (9.7, 10.0 and 9.3% respectively). COHORT RETENTION Among the 771 eligible women who attended at three-months, older women, those working in pombe shops or as mamalishe , those reporting fewer sexual partners in the last three months and women who were less mobile in terms of recent changes in accommodation and place of work had a significantly greater odds of re-attendance ( Table 5 ). The adjusted odds of re-attendance were five times higher in women aged ≥35years than those aged <20years. Marital status, ethnicity, education level and literacy were not associated with re-attendance (data not shown). 1. Attendance was defined on a four–level [0, 1, 2 and 3] ordinal scale as the number of visits made after a second visit at 3 mo (i.e. zero, one, two, or three additional visits) and modelled using ordinal logistic regression. The OR is the estimated odds ratio of ≥k visits vs